Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2953)	6/18/2010 8:56:13 AM
From: Jibacoa	1 Recommendation Respond to of 3722

After finding support at the $45 level, NVS has continued to move up without closing UGs.<g> It had a strong close yesterday and today should have no problem on going through the resistance at the $40 level.<g> bigcharts.marketwatch.com NVS announced that the FDA has approved Tasigna (nilotinib) 150 mg capsules for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive CML. Tasigna is now the first new therapeutic option for newly diagnosed patients since the introduction of Gleevec tablets. NVS has 2Qs of better revenues and earnings. In April it started the 2nd PI for PTH1-34 for treatment of postmenopausal osteoporosis. The LTD is moderate. It has good *CF and the Y around 3% isn't bad these days.<g> The ACTAY is $65.43 That could be doable, although there is a good amount of resistance at the $55 level.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2953)	6/21/2010 11:15:52 AM
From: mlkr	1 Recommendation Read Replies (2) \| Respond to of 3722

ARWR $1.30; Bernard similar offering in 2004 in a closed deal at higher prices I found ; By Michael Baron ARWR 1.34 1.32 1.30 1.28 NEW YORK (MarketWatch) -- Arrowhead Research Corp. /quotes/comstock/15*!arwr/quotes/nls/arwr (ARWR 1.26, -0.04, -3.08%) shares fell almost 5% to $4.45 on Friday after the company said it's sold a total of about 5.6 million shares of restricted common stock to York Capital Management and Knott Partners LP. The deal calls for York to acquire 4.2 million shares and Knott to get 1.4 million shares with both firms paying $3.50 per share. The firms will also receive warrants to purchase a total of 1.4 million shares at $5.04 each.